A mathematical model reveals circadian rhythms' impact on medication efficacy, particularly for neurological conditions like Parkinson’s disease and depression. The model focuses on dopamine reuptake ...
WPBF Channel 25 on MSN
'On the Record': November is Alzheimer's Awareness Month
WPBF 25 goes "On the Record" on Alzheimer's Disease and how medical professionals are working to combat the disease.
Sean Kelley on MSN
Zaya Younan: The Surprising Health Benefits of Premium Cigars
Discover the surprising health benefits of premium cigars in this eye-opening episode of Digital Social Hour. Our guest, a ...
Josh Harris, owner of the Washington Commanders, gifts President Trump a 47 jersey 🇺🇸 pic.twitter.com/O8rpfWVyeh Lenny ...
Bangkok Post on MSN
'Digital Bridge' offers hope for the paralysed
Spinal cord injury (SCI) remains one of the most devastating medical conditions, with no definitive cure to alleviate its ...
The Boston biotech founded by Harvard professor David Sinclair is testing whether cellular reprogramming can turn back the ...
ScienceAlert on MSN
Powerful New Antibiotic Was 'Hiding in Plain Sight' For Decades
Researchers have just identified a powerful new antibiotic – in a significant discovery made not by breaking new ground, but ...
The Galien Foundation Honors Michael J. Fox and 2025 Prix Galien Award Recipients NEW YORK, Oct. 31, 2025 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honoring ...
Researchers discovered that altering the body’s natural rhythm can help protect the brain from Alzheimer’s damage. By turning off a circadian protein in mice, they raised NAD+ levels and reduced ...
2don MSN
Vote to provide $3 billion for dementia institute a 'game-changer' for Texas researchers, families
Texas voters' approval of Proposition 14 during Tuesday's election is a boon for research into dementia, Alzheimer's, and ...
With the opening of its new clinic on Malta’s scenic Mellieha Bay, Ambio becomes the only transcontinental ibogaine provider ...
Highlights New analysis of ATH434-201 double blind trial strengthens efficacy signal at high dose levelPositive data from ATH434-202 open-label ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results